NHS Tayside has now considered your request dated 27 March 2019.

NHS Tayside wishes to advise you that there are exemptions applicable to the information requested. Please refer to the exemptions section of this correspondence.

**Extract from Request**

“Part 1
1) How many people are there with a diagnosis of MS in your Health Board area?
2) How many people with MS in your Health Board area (including the source for this number) are diagnosed as the following:
   a. Relapsing-Remitting MS
   b. Primary Progressive MS
   c. Secondary Progressive MS
   d. Benign MS
   e. Unconfirmed Type

Part 2
1) Are the following licenced drugs for multiple sclerosis (MS) approved for use on your local drugs formulary; and
2) Are the following licenced drugs for multiple sclerosis (MS) subject to any specific financial or clinical Avonex (interferon beta-1a) prescribing restrictions within your health board?
   a. Rebif (interferon beta-1a)
   b. Plegridy (peginterferon beta-1a)
   c. Betaferon (interferon beta 1b)
   d. Extavia (interferon beta 1b)
   e. Aubagio (teriflunomide)
   f. Copaxone (glatiramer acetate)
   g. Gilenya (fingolimod)
   h. Lemtrada (alemtuzumab)
   i. Tecfidera (dimethyl fumarate)
   j. Tysabri (natalizumab)
   k. Mavenclad (Cladribine)
   l. Ocrevus (ocrelizumab)
   m. Botox (botulinum toxin)
   n. Sativex (nabiximols)
   o. Fampride (fampridine)

Part 3
Please provide a breakdown of the number of people with MS currently being prescribed each of the licensed drugs shown in PART 2.”
Clarification (via email 09/04/19)

“As of today the 10th of April, it will provide a snapshot of the MS caseload and disease modifying therapy prescribing landscape at the time that the data is provided.”

Response

Part 1
1) NHS Tayside does not hold the information requested. However there have been 359 inpatients diagnosed with MS over the period 23 June 2017 – 9 April 2019.
2) As above. NHS Tayside has only one diagnosis code for MS; this diagnosis code would cover all types of MS diagnosis.

Part 2
1) All the licenced drugs for MS (above) are approved by NHS Tayside to use apart from Mavenclad (Cladribine), Ocrevus (ocrelizumab), Sativex (nabiximols) and Fampyra (fampridine).
2) All NHS Tayside MS drugs are used according to SMC recommendations for their licensed indication.

Part 3
Please see below a breakdown of the number of people with MS currently being prescribed each of the licenced drugs.

Where the values of statistics provided fall below 5 but are greater than 0, these statistics are represented by ‘<5’. Due to the small numbers of patients involved further detail cannot be provided as disclosure of the information may lead to the identification of individuals.

a. Avonex (interferon beta-1a) - 29
b. Rebif (interferon beta-1a) - 14
c. Plegridy (peginterferon beta-1a) - 15
d. Betaferon (interferon beta 1b) - <5
e. Extavia (interferon beta 1b) - 27
f. Aubagio (teriflunomide) - <5
g. Copaxone (glatiramer acetate) - 151
h. Gilenya (fingolimod) - 64
i. Lemtrada (alemtuzumab) - 23
j. Tecfidera (dimethyl fumarate) - 104
k. Tysabri (natalizumab) - 42
l. Mavenclad (Cladribine) - <5
m. Ocrevus (ocrelizumab) - 0
n. Botox (botulinum toxin) - 0
o. Sativex (nabiximols) - <5
p. Fampyra (fampridine) - 0

<table>
<thead>
<tr>
<th>Document Ref.</th>
<th>FOISA Exemption Applied</th>
<th>Justification</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGTFOISA6132</td>
<td>Section 17 – Information not held (Q1)</td>
<td>Information not held.</td>
</tr>
<tr>
<td></td>
<td>Section 38 (1)(a) – Personal information (Q3)</td>
<td>Information relating to an individual is personal information. Disclosure of information which would allow the identification of individuals would be in breach of confidentiality and Data Protection principles.</td>
</tr>
</tbody>
</table>
Under section 20 (1) of the Act, if you are dissatisfied with the way NHS Tayside has dealt with your request, you have a right to request a review of our actions and decisions in relation to your request, and you have a right to appeal to the Scottish Information Commission.

A request for an internal review must be made in writing no later than forty working days from receipt of this response and addressed to:

Tayside NHS Board Secretary
Tayside NHS Board Headquarters
Ninewells Hospital & Medical School
Dundee
DD1 9SY

If you are not content with the outcome of the internal review, you have the right to apply directly to the Scottish Information Commissioner for a decision. The Scottish Information Commissioner can be contacted at:

Scottish Information Commissioner
Kinburn Castle
Doubledykes Road
St Andrews
Fife
KY16 9DS

Or via the online appeal service: [www.itspublicknowledge.info/Appeal](http://www.itspublicknowledge.info/Appeal)

If you have any queries about this correspondence, please contact:

Information Governance Team
Maryfield House
30 Mains Loan
Dundee
DD4 7BT

Telephone - 01382 424413
E-mail: informationgovernance.tayside@nhs.net

Information Governance
NHS Tayside
18 April 2019